Drug Delivery Business

Catalent beats The Street in Q1, raises revenue guidance

By

CatalentCatalent (NYSE:CTLT) shares dipped today despite first-quarter financial results that beat the consensus forecast.

The Somerset, New Jersey-based company posted profits of $93 million, or 49¢ per share, on sales of $1.025 billion for the three months ended Sept. 30, 2021, for a 13.4% bottom-line gain on sales growth of 21.2%.

Get the full story at our sister site, Drug Delivery Business News.

IN CASE YOU MISSED IT

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].